|Bristol Myers Squibb Co., of New York||Mavacamten||Allosteric modulator of cardiac myosin||Obstructive hypertrophic cardiomyopathy||FDA accepted the NDA; PDUFA action date is Jan. 28, 2022|
|Johnson & Johnson, of New Brunswick, N.J., and Idorsia Ltd., of Allschwil, Switzerland||Ponvory (ponesimod)||Sphingosine-1-phosphate receptor 1 modulator||Relapsing forms of multiple sclerosis||FDA approved the drug|
|Kiniksa Pharmaceuticals Ltd., of Hamilton, Bermuda||Arcalyst (rilonacept)||Recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling||Recurrent pericarditis||FDA approved the drug; commercial launch expected in April 2021|
|The Russian Direct Investment Fund, of Moscow||Sputnik V||Adenovirus-based vaccine||COVID-19 prophylaxis||Vaccine was approved in the Republic of Seychelles|
For more information about individual companies and/or products, see Cortellis.